Semaglutide, body recomposition, and what week 13 actually tells us

What's this video probably claiming?

Based on the caption, this creator is sharing a week 13 semaglutide update where the scale went up, but body fat percentage dropped and muscle mass increased. The implied claim is that body recomposition, losing fat while gaining or preserving muscle, is happening simultaneously on semaglutide. This is a meaningful and increasingly common narrative on GLP-1 content: that the medication helps people lose "the right kind of weight." The hashtag medspa suggests she may be accessing semaglutide through a medical spa rather than a traditional clinical setting, which is worth flagging. The framing around weekly weigh-ins and body composition metrics suggests she is tracking more than just scale weight, which is actually a more sophisticated approach than most GLP-1 social media content. The core claim, body recomposition on semaglutide with deliberate muscle preservation, is plausible but requires some unpacking.

What does the science actually show?

The honest answer is: semaglutide alone does not produce clean body recomposition. The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) showed 14.9% mean body weight loss on 2.4mg semaglutide weekly, but lean mass loss accompanied fat loss in a roughly 1:4 ratio, meaning for every 4 pounds of fat lost, about 1 pound came from lean tissue. That is not ideal. A 2023 analysis in Obesity (Rubino et al.) reinforced that muscle preservation during GLP-1 therapy requires active resistance training and adequate protein intake. The drug does not protect muscle on its own. At week 13, total weight loss is likely modest, probably in the 5-8% range based on typical titration timelines, so small week-to-week fluctuations in body composition metrics from consumer devices like bioelectrical impedance scales carry significant measurement error. The directional trend the creator describes is biologically possible, but the precision implied by weekly BIA readings is not clinically reliable.

Where does the social media noise diverge from clinical reality?

The biggest gap here is measurement accuracy. Most body fat percentage readings from home scales use bioelectrical impedance analysis, which can swing 3-5 percentage points based on hydration, time of day, and food intake (Kyle et al., 2004, Clinical Nutrition). A single-week comparison showing muscle gain on a BIA device is almost certainly noise, not signal. That does not mean the creator is wrong about her overall trajectory, but framing weekly BIA numbers as evidence of muscle gain overstates what those tools can actually detect. The second issue is the medspa hashtag. Semaglutide accessed outside structured clinical care often lacks the monitoring that would contextualize these numbers, including DEXA scans, which are the actual gold standard for body composition measurement. Social media tends to treat week-over-week fluctuations as meaningful data. Clinically, body recomposition assessments need at minimum 8-12 weeks of consistent tracking with validated tools.

What should you actually know?

If you are on semaglutide and trying to preserve muscle, the research does support that it is possible, but the drug is not doing that work. A 2024 study in JAMA Network Open (Bilet et al.) found that combining GLP-1 therapy with resistance training significantly improved lean mass outcomes compared to medication alone. Protein intake matters too: most clinical guidance for people in a caloric deficit from GLP-1 suppressed appetite points toward 1.2-1.6g of protein per kilogram of body weight daily. The scale going up while body composition improves is a real phenomenon and not a contradiction. But tracking it accurately requires tools more reliable than a consumer BIA scale used weekly. The creator's instinct to look beyond scale weight is genuinely good. The specific numbers she's reading week to week deserve more skepticism than she is probably giving them. A DEXA scan every 3 months would tell her something real.